New pathophysiological mechanisms in irritable bowel syndrome

被引:145
作者
Barbara, G [1 ]
De Giorgio, R [1 ]
Stanghellini, V [1 ]
Cremon, C [1 ]
Salvioli, B [1 ]
Corinaldesi, R [1 ]
机构
[1] Univ Bologna, Dept Internal Med & Gastroenterol, I-40126 Bologna, Italy
关键词
D O I
10.1111/j.1365-2036.2004.02036.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Irritable bowel syndrome (IBS) is a functional, multifactorial disease characterized by abdominal pain and erratic bowel habit. Changes in gastrointestinal motor function, enhanced perception of stimuli arising from the gut wall and psychosocial factors are thought to be major contributors for symptom generation. In recent years, several additional factors have been identified and postulated to interact with these classical mechanisms. Reduced ability to expel intestinal gas with consequent gas trapping and bowel distension may contribute to abdominal discomfort/pain and bloating. Abnormal activation of certain brain regions following painful stimulation of the rectum suggests altered processing of afferent signals. An acute gastrointestinal infection is now a recognized aetiological factor for symptom development in a subset of IBS patients (i.e. post-infectious IBS), who are probably unable to down-regulate the initial inflammatory stimulus efficiently. Furthermore, low-grade inflammatory infiltration and activation of mast cells in proximity to nerves in the colonic mucosa may also participate in the frequency and severity of perceived abdominal pain in post-infectious and non-specific IBS. Initial evidence suggests the existence of changes in gut microflora, serotonin metabolism and a genetic contribution in IBS pathophysiology. These novel mechanisms may aid a better understanding of the complex pathophysiology of IBS and to develop new therapies.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 103 条
  • [31] Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome
    Dunlop, SP
    Jenkins, D
    Spiller, RC
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (07) : 1578 - 1583
  • [32] Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome
    Dunlop, SP
    Jenkins, D
    Neal, KR
    Naesdal, J
    Borgaonker, M
    Collins, SM
    Spiller, RC
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (01) : 77 - 84
  • [33] El-Salhy M, 1999, SCAND J GASTROENTERO, V34, P1007
  • [34] Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats
    Eutamene, H
    Theodorou, V
    Fioramonti, J
    Bueno, L
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2003, 553 (03): : 959 - 966
  • [35] Jejunal sensorimotor dysfunction in irritable bowel syndrome: Clinical and psychosocial features
    Evans, PR
    Bennett, EJ
    Bak, YT
    Tennant, CC
    Kellow, JE
    [J]. GASTROENTEROLOGY, 1996, 110 (02) : 393 - 404
  • [36] Bile salts, intestinal microflora and enterohepatic circulation
    Floch, MH
    [J]. DIGESTIVE AND LIVER DISEASE, 2002, 34 : S54 - S57
  • [37] LIFE EVENTS, PSYCHIATRIC-ILLNESS AND THE IRRITABLE-BOWEL-SYNDROME
    FORD, MJ
    MCCMILLER, P
    EASTWOOD, J
    EASTWOOD, MA
    [J]. GUT, 1987, 28 (02) : 160 - 165
  • [38] Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome
    Fukudo, S
    Nomura, T
    Hongo, M
    [J]. GUT, 1998, 42 (06) : 845 - 849
  • [39] Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?
    Gonsalkorale, WM
    Perrey, C
    Pravica, V
    Whorwell, PJ
    Hutchinson, IV
    [J]. GUT, 2003, 52 (01) : 91 - 93
  • [40] Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome
    Gwee, KA
    Collins, SM
    Read, NW
    Rajnakova, A
    Deng, Y
    Graham, JC
    McKendrick, MW
    Moochhala, SM
    [J]. GUT, 2003, 52 (04) : 523 - 526